Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients

Thumbnail
View/Open
Accepted version (21.14Mb)
Date
2022-04-30
ICR Author
Au, Lewis
Author
Au, L
Type
Thesis or Dissertation
Metadata
Show full item record
Abstract
The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic settings. Intratumour heterogeneity (ITH) is a pervasive phenomenon of ccRCC. Studies to date examining putative biomarkers have used single-region biopsies and therefore not accounted for ITH. Moreover, genomic and tumour immune microenvironment (TME) changes under therapy have not been examined, which could inform potential mechanisms of anti-VEGF/CPI synergy and renal dynamic correlates of therapy response and resistance. I examined the determinants of anti-PD-1 monotherapy response in multiregion tumour samples collected pre- and post-treatment within a prospective phase II clinical trial. I discovered maintenance of previously expanded T cell clones underpin nivolumab response. Within another prospective clinical study which examined effects of axitinib in patients with metastatic ccRCC, I show preliminary data from driver mutation and gene expression profiling of longitudinal, multiregion tumour samples. Separately, using a tumour-informed, phylogenetic approach to profile circulating tumour DNA, I showed clonal phylogeny of ccRCC can be recapitulated by peripheral sampling as a potential means of circumnavigating the shortcomings of tissue-based biopsies. From March 2020, the SARS-CoV-2 pandemic halted routine laboratory operations for 18 months. During this time and as an emergency response, my doctoral studies pivoted towards uncovering the immunological basis of poor outcomes to SARS-CoV-2 infection and functional immunity against SARS-CoV-2 variants of concern (VOC) and following COVID-19 vaccination in cancer patients. I report the rapid establishment of a prospective, pan-cancer study (CAPTURE) for longitudinal immune profiling of cancer patients in the context of SARS-CoV-2 and COVID-19 vaccines. CAPTURE provided a large dataset (n=784 patients enrolled to date), within which I describe a case of cytokine release syndrome following BNT162b2 vaccination in a patient under anti-PD-1 therapy; and show patients with hematological malignancies had impaired neutralising antibody responses against VOC that was disease lineage and anti-CD20 treatment-specific, in the setting of both SARS-CoV-2 infection (n=118) and COVID-19 vaccines (n=585).
URI
https://repository.icr.ac.uk/handle/internal/5092
Collections
  • Clinical Studies
Subject
Theses, Doctoral
Renal Cancer
Vaccines
Covid
Research team
Melanoma and Kidney Cancer
Language
eng
License start date
2022-04-30
Citation
2022
Publisher
Institute of Cancer Research (University Of London)

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.